Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

105.12 +3.52 (+3.46%)

Streaming Delayed Price Updated: 2:46 PM EDT, Jul 29, 2026 Add to My Watchlist

Price and Volume

Volume	442,933
Open	102.12
Bid (Size)	104.57 (100)
Ask (Size)	105.49 (100)
Prev. Close	101.61
Today's Range	100.99 - 105.13
52wk Range	18.08 - 107.99
Shares Outstanding	60,648,883
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

July 02, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

June 29, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+164.9%	+164.9%
1 Month	+9.9%	+9.9%
3 Month	+25.6%	+25.6%
6 Month	+109.0%	+109.0%
1 Year	+371.8%	+371.8%

More News

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Participate in Two Investor Conferences

May 26, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗

May 18, 2026

Via The Motley Fool

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗

May 18, 2026

Via The Motley Fool

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

Via The Motley Fool

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

Via The Motley Fool

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

Via The Motley Fool

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

May 05, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 01, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗

April 19, 2026

Via The Motley Fool

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 06, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗

April 06, 2026

Via The Motley Fool

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 12, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Via Finterra

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

March 10, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

March 09, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗

March 09, 2026

Via Stocktwits

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

March 09, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

March 09, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

March 08, 2026

From Dianthus Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?

Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?

Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?

The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market

What is the current price of Dianthus Therapeutics, Inc. - Common Stock?

The current price of Dianthus Therapeutics, Inc. - Common Stock is 105.12

When was Dianthus Therapeutics, Inc. - Common Stock last traded?

The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 07/29/26 02:46 PM ET

What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?

The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 6.38B

How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?

Dianthus Therapeutics, Inc. - Common Stock has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.